FDA’s review date for BMS’ ide-cel sneaks under the CVR wireThe FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, Share XFDA’s review date for BMS’ ide-cel sneaks under the CVR wirehttps://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/
Patient-to-Patient Supply for Cell Immunotherapies SummitAchieving Standardization & Operational Excellence in Vein-to-Vein Supply As an increasing number of candidates enter the clinic and Share XPatient-to-Patient Supply for Cell Immunotherapies Summithttps://pharmaphorum.com/events/patient-to-patient-supply-for-cell-immunotherapies-summit/
2nd Macrophage-directed Therapies SummitHarnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Share X2nd Macrophage-directed Therapies Summithttps://pharmaphorum.com/events/2nd-macrophage-directed-therapies-summit/
Kiadis shares yo-yo on cell therapy trial for COVID-19Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer Share XKiadis shares yo-yo on cell therapy trial for COVID-19https://pharmaphorum.com/news/kiadis-shares-yo-yo-on-cell-therapy-trial-for-covid-19/
Preparing for an influx of cell and gene therapy approvalsCell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has Share XPreparing for an influx of cell and gene therapy approvalshttps://pharmaphorum.com/views-analysis-sales-marketing/preparing-influx-cell-gene-therapy-approvals/
GSK begins cancer cell therapy tie-up with ImmaticsCancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology. Share XGSK begins cancer cell therapy tie-up with Immaticshttps://pharmaphorum.com/news/gsk-begins-cancer-cell-therapy-tie-up-with-immatics/
How cell and gene therapies are transforming pharma deal-makingAfter decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to Share XHow cell and gene therapies are transforming pharma deal-makinghttps://pharmaphorum.com/r-d/views-analysis-r-d/how-cell-and-gene-therapies-are-transforming-pharma-deal-making/
Kiadis sheds half its staff as lead cell therapy bombsDutch biotech Kiadis Pharma has abandoned its lead cell therapy and axed half its workforce after a failed Share XKiadis sheds half its staff as lead cell therapy bombshttps://pharmaphorum.com/news/kiadis-sheds-half-its-staff-as-lead-cell-therapy-bombs/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
